Background
Introduction
Cancer of the nasopharynx is endemic in East Asia and South-East Asia [1, 2] . In Singapore, it is the 8 th most common cancer in males, with an age-standardized incidence of 9.5 per 100,000
per year [3] . This is in contrast to the United States and the rest of the world, with less than 1 case per 100,000 per year [4] . Ethnic differences in its etiology and presentation have been described. The keratinizing squamous cell carcinoma (WHO type 1) is more common among Caucasians in Western populations, while the EBV-associated undifferentiated variant (WHO type 2b) is seen predominantly among Chinese living in Southern China, Hong Kong, Taiwan, and Singapore [4] [5] [6] . Given its radiosensitive nature, chemo-radiation is the mainstay of treatment [7] [8] [9] [10] with favorable overall 5-year survival rates of 75% to 83% [11, 12] . However, recurrent disease following definitive chemo-radiation occurs in approximately 10-15% of patients with distant metastases contributing to a poor outcome in these patients [13, 14] . The epidemiology and survival outcomes of nasopharyngeal carcinoma (NPC) are well described in Chinese populations. However, in the multi-ethnic society of Singapore, the epidemiology and the risk factors for loco-regional recurrence and survival of non-Chinese NPC patients are not well described. Specifically, whether non-Chinese patients constitute a distinct population with a different clinical outcome is unknown. Therefore, the aim of this study is to determine if non-Chinese NPC patients have a different clinical outcome. Our secondary aim is to identify predictive factors for survival and recurrence of NPC patients in a multi-ethnic patient population in Singapore.
Materials and Methods
A retrospective chart review of clinical records was conducted and 586 NPC patients diagnosed at the National University Hospital, Singapore between January 2002 and October 2012 were identified. All patients who were treated and with follow-up data were included. Twenty-eight (4.8%) patients were excluded as they did not initiate or complete treatment at our center, leaving 558 (95.2%) patients for analyses. Patients' follow-up was assessed up to December 2013. All information on patient demographics was obtained through patient clinical records, with approval from our local institutional review board (National Healthcare Group Ethics Committee Singapore; approval code 00418-AMD0002). Patient's records and relevant information were anonymized and de-classified prior to analysis. metastases. All patients were staged according to the American Joint Committee on Cancer (AJCC) 7 th edition criteria [15] . The extent of local disease was determined either by computed tomography (CT) or magnetic resonance imaging (MRI) of the post-nasal space and neck. Assessment of distant metastasis was performed using either a combination of CT-thorax and abdomen and bone scan, or with a single whole body positron emission tomography-computed tomography (PET-CT) scan. At our institution, all newly diagnosed NPC patients were presented at the head and neck cancer multi-disciplinary board comprising otolaryngologists, radiation and medical oncologists, radiologists and pathologists. The standard treatment protocol at our institution during the study period was to administer radiotherapy alone for early stage (Stage I and II) disease, with the addition of concurrent chemotherapy for late stage (Stage III, IVA, and IVB) disease. 3-D conformational radiotherapy (3-D CRT) or intensity-modulated radiotherapy (IMRT) were the primary radiotherapy techniques administered with IMRT being the standard of radiotherapy treatment from 2006. Platinum-based chemotherapy along with 5-fluorouracil (5-FU) was the primary chemotherapy regimen with a small cohort of stage IV patients receiving neo-adjuvant chemotherapy as a trial protocol.
Classification of Ethnicity
For this study, ethnicity or race was determined by patients' national identity records and retrieved from hospital registration records. As the Chinese comprised the majority of ethnicities, non-Chinese patients were grouped collectively for the purpose of analyses.
Statistical Methods
We defined the starting point of all events as the date of disease diagnosis, and the times to the following endpoints were determined in months: disease specific survival (DSS-death due to NPC or treatment complications), overall survival (OS-death from any cause), loco-regional recurrence (LRR-recurrent disease in the nasopharynx or neck), and distant failure (DFmetastatic recurrence). Deaths due to intercurrent diseases, coroners' cases, or unknown causes were considered censorings for OS. For the determination of 3-year and 5-year OS and DSS, only patients with 3 years and 5 years follow-up were considered respectively. In the assessment of disease recurrence, only patients with non-metastatic disease who received definitive treatment with curative intent were considered for analysis.
Statistical tests were performed using IBM SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). Univariate analyses were performed using chi-square tests; ordinal chi-square tests were used to assess linearity in ordinal variables. Survival times were calculated using the Kaplan-Meier method and the differences were compared using log-rank tests. Multivariate analyses were performed using the Cox hazard regression model. A p-value of less than 0.05 was used to indicate statistical significance for all tests.
Results

Patient and Disease Characteristics
The mean age at diagnosis was 51.8 (range 14 to 94). There were 409 (73.3%) males and 149 females (26.7%). The distribution of ethnicity was: 476 Chinese (85.3%), 57 Malays (10.2%), and 25 of other ethnic groups (4.5%). Patients of other ethnicities include Indian (6, 1.1%), Caucasian (2, 0.4%), Kenyan (1, 0.2%) and others of mixed ethnicities (16, 2.9%). A majority of these cancers were the non-keratinizing undifferentiated WHO type 2b variant (95.5%) while the WHO type 2a variant (keratinizing undifferentiated) and WHO type 1 variant (squamous cell carcinoma) comprised the remaining 2.5% and 1.3% of our patient cohort respectively. We were unable to retrieve the histological reports of 4 (0.7%) patients, although the clinical records of diagnosis and treatment of NPC were evident in these patients. The median duration of follow-up was 41 months.
Our patient demographics and AJCC staging distribution are summarized in Table 1 . In patients with M1 disease at diagnosis, the most common site of metastases was bone (34/53, 64.2%), followed by lung (20/53, 37.7%) and liver (15/53, 28.3%). Other sites accounted for 13.2% (7/53). These include eye (1), gastric/celiac lymph nodes (1), bone marrow (1), mediastinal/peritoneal lymph nodes (1), aortopulmonary lymph nodes (1), spleen (1) and adrenals (1).
Ethnic Differences
On univariate analysis, patients of non-Chinese ethnicity were more likely to be associated with higher nodal disease (p = 0.049), compared with those of Chinese ethnicity. In terms of age, gender, histology, AJCC stage and T classification, there was no significant difference between Chinese and non-Chinese. Given that Malays were the predominant non-Chinese cohort (57/82, 69.5%), a sub-analysis of comparison was performed. Similarly, Malays were more likely to present with a higher AJCC stage at diagnosis (p = 0.015), higher T and N disease (p = 0.033 and p = 0.016 respectively). Table 2 summarizes these characteristics. 
Overall and Disease Specific Survival
The 3-year and 5-year overall survival (OS) rates of our cohort were 79.3% and 69.9%, while disease-specific survival (DSS) rates were 82.8% and 70.3% respectively. The mean OS was 96.1 months (95% CI 91.1-101.1) while the mean DSS was 106.6 months (95% CI 102.0-111.3). The survival curves for OS and DSS are shown in Fig 1A and 1B . The 3-year and 5-year OS for non-metastatic patients who received treatment with curative intent was 84.6% and 74.7% respectively, while 3-year and 5-year DSS was 88.3% and 81.5% respectively.
Predictive Factors for Overall Survival and Disease Specific Survival
On univariate analysis, advanced age (p<0.001), higher T classification (p<0.001), higher N classification (p<0.001), and metastatic disease at presentation (p<0.001) were found to be significantly associated with poor OS, while patients with advanced age (p = 0.009), metastatic disease at presentation (p<0.001) and a higher T and N disease (p = 0.015 and p<0.001 respectively) were associated with poor DSS. These results are summarized in Table 4 . Among nonChinese patients, the presence of distant metastasis was the only factor associated with a poorer overall survival and disease specific survival. On multivariate analysis, age was significantly associated with worse OS (Hazard Ratio = 1.028 for each additional year, p<0.001, 95% CI 1.013-1.044). Among the disease factors, N2 disease (H.R. 1.75, p = 0.036, 95% CI 1.04-2.96), N3 disease (H.R. 2.99, p<0.001, 95% CI 1.69-5.27) and metastatic disease at presentation (H.R. 5.54, p<0.001, 95% CI 3.59-8.57) Table 3 , and are represented by survival curves in Fig 2A and 2B. doi:10.1371/journal.pone.0126108.g001 
Predictive Factors for Loco-Regional Recurrence and Distant Failure
On both univariate and multi-variate analysis, there were no predictive factors associated with LRR. Ethnicity was not a risk factor for developing LRR. There was no difference in the LRR rate between the Chinese and non-Chinese (p = 0.481).
On univariate analysis, a higher N disease (p<0.001) was associated with an increased risk of distant failure after primary treatment. On multivariate analysis, age (H.R. 1.02 for each additional year, p = 0.044, 95% CI 1.001-1.04), N2 disease (H.R. 2.31, p = 0.017, 95% CI 1.16-4.60) and N3 disease (H.R. 5.41, p < 0.001, 95% CI 2.59-11.33) were independently associated with distant failure.
Subgroup analysis within the N3 group of patients revealed a higher risk of distant failure in the N3b group compared with the N3a group (H.R. 2.790, 95% CI 1.097-7.092, p = 0.031). The Table 6 summarizes the factors associated with LRR and distant failure.
Discussion
Nasopharyngeal carcinoma is an endemic cancer among Chinese in Southern China and Southeast Asia. Unsurprisingly, our study showed a predominance of Chinese in our NPC cohort (85.3%). Genetic and environmental factors have been implicated in the pathogenesis of NPC in Chinese [16, 17] . This has been illustrated in epidemiological studies where Chinese from Southern China and Hong Kong who migrated to the United States of America were found to have a similarly high incidence of NPC compared to their indigenous population, but with decreasing risks with each successive generation born in the United States [18] . Genomewide association studies have also supported a genetic basis with the HLA region being identified as an at-risk locus among Chinese populations [19] .
In the multi-ethnic society of Singapore, the epidemiology of NPC among non-Chinese is not well defined. Our study demonstrated that the non-Chinese comprised 14.7% of our cohort of NPC patients, with the Malays being the predominant ethnic group (69.5%) developing this disease in our non-Chinese cohort. Interestingly, the endemic non-keratinizing undifferentiated WHO type 2b variant (EBV-associated) was predominant in all ethnic groups suggesting that environmental factors may account for this observation [20] . Another explanation could be attributed to genetic cofactors such as a history of intermarriage between the Malay indigenous population and Chinese ancestors in Southeast Asia [17] . However, this hypothesis could not be confirmed given the retrospective nature of this study. Certainly, this genetic basis may occur since specific HLA haplotypes have been identified among nasopharyngeal carcinoma patients [21] . Despite being a low-risk ethnic group for cancer in Singapore, the increasing incidence of cancer including nasopharyngeal carcinoma among the Malay population is a cause of concern necessitating further research into this phenomenon [22] . A more concerning finding was that Malay patients presented with a more advanced primary and nodal disease at presentation than the Chinese. This observation may be attributed to a lower index of suspicion of NPC among referring primary care practitioners since NPC is traditionally thought of as a disease afflicting mainly the Chinese. Additionally, differences in cultural attitudes and disease awareness among ethnicities may also contribute to a delayed presentation. This cultural bias of poorer awareness was demonstrated among non-Chinese patients who presented with a more advanced breast cancer in Singapore [23, 24] . This study serves to highlight the need for increased awareness of NPC in non-Chinese patients among general practitioners in our population.
Despite Malays presenting with a more advanced disease, their survival and disease control rates were not significantly different when compared to the Chinese following definitive therapy. Given that the EBV-associated WHO type 2b variant is ubiquitously found in both Chinese and non-Chinese, it is likely that the radiosensitive nature of this variant portends a favorable prognosis even when detected at a more advanced stage. Certainly, a type II error may also account for this observation due to the small sample size of the non-Chinese population (57/558, 10.2%). Larger scale multi-center studies may be necessary to overcome this limitation.
Previous studies have reported that age, male gender, and advanced T and N disease were poor prognostic factors for NPC [14, [25] [26] [27] [28] [29] . In our series, age, advanced N disease and metastatic disease at presentation were associated with a poorer outcome. Similar observations have also been described by Lu et al. where an advanced N disease was the predominant predictive factor of poor outcome [29] . It is possible that with advances in radiotherapy techniques and experience, a high loco-regional control rate is achievable and hence, a more advanced T disease may no longer be as important a prognostic factor as it used to be. However, a temporal comparison of outcomes between patient cohorts will be required to validate this hypothesis.
Similarly, we did not find any predictors of loco-regional recurrence (LRR) in our cohort compared to previous studies in which age and late T disease were significant predictors [25, 27, 30, 31] . As these studies were conducted in the late 1990s and early 2000s, advances in radiotherapy techniques may have accounted for the improved loco-regional control rate seen in our study.
Lastly, a more advanced nodal status (N2 and N3 disease) was associated with an increased risk of distant failure. This finding was consistent with previous studies [14, 28, 29, 31] . Specifically, patients with N3 nodal disease had the highest risk of distant failure after primary chemo-radiation. Additionally, patients with N3b disease are at an even higher risk of distant failure compared to those with N3a disease. Whatever the mechanisms of distant failure, the outcome of this group of patients remains poor. These results reflect how distant failure still remains the primary cause of treatment failure and mortality, even while local disease control has improved with advances in radiotherapy techniques and successful surgical salvage [32] . Based on this observation, neoadjuvant chemotherapy and other novel strategies should be investigated in patients with N3 disease in order to minimize the risk of distant relapse.
Conclusion
In a multi-ethnic society in Singapore, non-Chinese are more likely to present with higher nodal disease than the Chinese. This however does not translate into poorer survival outcomes. N2 or N3 disease is associated with a higher risk of distant relapse and poor overall survival. This group of patients may benefit from systemic or targeted therapy which needs to be addressed in prospective clinical studies.
